Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
NCT07037433 on ClinicalTrials.gov · last registry update 2026-09-03
An unusually large phase 3: 12,800 participants, more than double the 424 typical for the stage. Due to report 30 June 2028. Sponsors move these dates routinely; any movement since this site started watching is listed below. maridebart cafraglutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended.
- Status
- RECRUITING
- Phase
- P3
- Sponsor
- Amgen
- Sponsor type
- Industry
- Enrollment
- 12,800
- Started
- 2025-07-25
- Primary completion
- 2028-06-30 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Time to First Occurrence of a Composite Endpoint Consisting of: CV Death, Myocardial Infarction (MI), or Ischemic Stroke (3-point Major Adverse Cardiac Events [3-P MACE])
Conditions studied
Atherosclerotic Cardiovascular Disease · Overweight · Obesity
Every field above is taken directly from the registry record. See all detected changes across the class, or the maridebart cafraglutide page for this molecule’s full trial and approval history.